Tradestie Institutional Equity Comparison Engine

ICCC vs ANRO โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

ICCC Overall Edge

ICCC Captures Institutional Edge (2โ€“2 Pillars ยท 8โ€“1 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Immucell Corp (ICCC) driven by superior Valuation, Growth & Margin while ANRO counters with relative strength in Momentum & Technical, Options & Structure. Fundamentally, ICCC trades at N/M Forward P/E with 15.2% operating margin (+11.5% YoY revenue) versus ANRO at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, ICCC sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against ANRO sits in BREAKDOWN (8th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner ICCC
ICCC N/M vs ANRO N/M Fwd P/E
Growth & Margin Winner ICCC
Op Margin 15.2% vs 0.0% ยท YoY +11.5% vs +0.0%
Momentum & Technical Winner ANRO
1Y +88.8% vs +138.9% ยท 52W Pos 91% vs 61%
Options & Structure Winner ANRO
UNCLASSIFIED (N/A IV) vs BREAKDOWN (8th %ile IV)
ICCC NASDAQ
Immucell Corp
In Vitro & In Vivo Diagnostic Substances
$11.42
+6.23% 1D
Market Cap $97.7M
1M Return +6.23%
1Y Return +88.76%
Forward P/E N/M
Unified AI Score
43.8 / 100 HOLD
Tech 15.0 Fund 48.0 Flow 50.0 Mom 50.0
ANRO NYSE
Alto Neuroscience Inc.
Pharmaceutical Preparations
$27.12
-8.19% 1D
Market Cap $1.2B
1M Return +23.61%
1Y Return +138.94%
Forward P/E N/M
Unified AI Score
29.2 / 100 SELL
Tech 50.0 Fund 33.0 Flow 65.0 Mom 40.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: ICCC +88.76% ANRO +138.94% Spread: +50.18 pp (ANRO Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
ICCC TTM Op. Margin: 15.2% ANRO TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ICCC vs ANRO. Trailing 12-month operating profitability (ICCC 15.2% vs ANRO 0.0%) and valuation multiples (ICCC N/M vs ANRO N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: ICCC (8) vs ANRO (1)
Institutional Metric ICCC ANRO Criterion Row Winner
Market Capitalization Scale $97.7M $1.2B Larger Scale ANRO
Trailing P/E Ratio Valuation 56.6x N/M Lower Multiple ICCC
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth +11.5% +0.0% Higher Growth ICCC
Operating Margin (TTM) Profitability 15.2% 0.0% Higher Margin ICCC
Net Profit Margin Profitability 2.6% 0.0% Higher Margin ICCC
Return on Equity (ROE) Capital Efficiency 2.6% -46.7% Higher ROE ICCC
52-Week Range Position Momentum 91% ($5โ€“$12) 61% ($11โ€“$37) Stronger Trend ICCC
Beta / 30D Volatility Risk Regime 0.24ฮฒ ยท 46% Vol 1.95ฮฒ ยท 90% Vol Lower Realized Risk ICCC
Unified Institutional Score Composite Signal 43.8 / 100 (HOLD) 29.2 / 100 (SELL) Higher Composite ICCC

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full ICCC vs ANRO Buy Guide
ICCC UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live ICCC Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
ANRO BREAKDOWN
57d in phase ยท OBV ACCUMULATION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 8th %ile
IV Regime Compressed (<25th %ile)
Live ANRO Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither ICCC nor ANRO registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.